The peripheral serotonergic system and platelet aggregation in cyclosporin A-induced hypertensive rats

Thrombosis Research

Volumn 96, Issue 5, 1999, Pages 365-372

  Reis, Flávio ^a   Tavares, Paula ^a   Ribeiro, C A Fontes ^a   Antunes, Ferrer ^b   Teixeira, Frederico ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Aggregation; Cyclosporin A; Hypertension; Serotonin; Thromboembolic complications

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; CYCLOSPORIN A; SEROTONIN; THROMBOXANE A2; THROMBOXANE B2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG INDUCED DISEASE; HYPERTENSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SCHOOL CHILD; SEROTONINERGIC SYSTEM; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOEMBOLISM;

ANIMALS; BLOOD PLATELETS; BLOOD PRESSURE; CELL SIZE; COLLAGEN; CYCLOSPORINE; HYPERTENSION; MALE; PLATELET AGGREGATION; PLATELET COUNT; RATS; RATS, WISTAR; SEROTONIN; THROMBOXANE A2; THROMBOXANE B2; TIME FACTORS;

EID: 0032762622     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00115-2     Document Type: Article

References (34)

1. Borel J.F., Di Padova F., Mason J., Quesniaux V., Ryffel B., Wenger R. Pharmacology of cyclosporine (Sandimmune). I. Introduction. Pharmacol Rev. 41:1989;239-242.
2. Kahan B.D. Cyclosporine. N Engl J Med. 321:1989;1725-1738.
3. Langford C.A., Klippel J.H., Balow J.E., James S.P., Sneller M.C. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune diseases. Ann Intern Med. 129:1998;49-58.
4. Schachter M. Cyclosporine A and hypertension. J Hypertens. 6:1988;511-516.
5. Mimran A., Mourad G., Ribstein J., Halimi J.-H. Cyclosporin-associated hypertension. Laragh J.H., Brenner B.M. Hypertension. Pathophysiology, Diagnosis and Management:1995;2459-2469 Raven Press, New York.
6. Sander M., Victor R.G. Hypertension after cardiac transplantation. pathophysiology and management Curr Opin Nephrol and Hypertens. 4:1995;443-451.
7. Ventura H.O., Malik F.S., Mehra M.R., Stapleton D.D., Smart F.W. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol. 12:1997;375-381.
8. Vanrenterghem Y., Roels L., Lerut T., Gruwez L., Michielsen P., Gresele P., Deckmyn H., Colucci M., Arnout J., Vermylen J. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet. I:1985;999-1002.
9. Muraki T., Sasaki Y., Gidding J.C., Ishii H., Kaneko T., Yamamoto J. Antithrombotic effects of FK506 versus prothrombotic effect of cyclosporine in vivo. Transplantation. 60:1995;308-309.
10. Miller B.W., Hmiel S.P., Schnitzler M.A., Brennan D.C. Cyclosporine as cause of thrombotic microangiopathy after renal transplantation. Am J Kidney Dis. 29:1997;813-814.
11. Oskarsson H.J., Hofmeyer T.G., Olivari M.T. Cyclosporine impairs the ability of human platelets to mediate vasodilation. Hypertension. 29:1997;1314-1321.
12. Grace A.A., Barradas M.A., Mikhailidis D.P., Jeremy J.Y., Moorhead J.F., Sweny P., Dandona P. Cyclosporine A enhances platelet aggregation. Kidney Int. 32:1987;889-895.
13. González-Correa J.A., De La Cruz J.P., Lucena M.I., Sánchez de la Cuesta F. The effect of cyclosporine A on platelet aggregation and thromboxane/prostacyclin balance in a model of extrahepatic cholestasis in the rat. Thromb Res. 81:1996;367-381.
14. Malyszko J., Pawlak D., Pawlak K., Malyszko J.S., Buczko W., Azzadin A., Mysliwiec M. Platelet aggregation and peripheral serotonergic system in kidney transplant recipients treated with cyclosporine. Transplant Proc. 28:1996;1954-1957.
15. Jorkasky D.K., Fisher C.A., Stahl R.F., Addonizio V.P., Glickman J.D. The effects of cyclosporine on human platelet aggregation and thromboxane release. Transplant Proc. 21:1989;948-949.
16. Bossaller C., Forstermann U., Hertel R., Olbsricht C., Reschke V., Fleck E. Cyclosporin A inhibits endothelium-dependent vasodilatation and vascular prostacyclin production. Eur J Pharmacol. 165:1989;165-169.
17. Baker L.R.I., Tucker B., Kovacs I.B. Enhanced in vitro hemostasis and reduced thrombolysis in cyclosporine-treated renal transplant recipients. Transplantation. 49:1990;905-909.
18. Levi M., Wilmink J., Buller H.R., Surachno J., Ten Cate J.W. Impaired fibrinolysis in cyclosporin-treated renal transplant recipients. Transplantation. 54:1992;978-983.
19. Cohen H., Neild G.H., Patel R., Mackie I.J., Machin S.J. Evidence for chronic platelet hyperaggregability and in vivo activation in cyclosporin-treated renal allograft recipients. Thromb Res. 49:1988;91-101.
20. Ueda D., Suzuki K., Malyszko J., Pietraszek M.H., Takada Y., Takada A., Kawabe K. Fibrinolysis and serotonin under cyclosporine A treatment in renal transplant recipients. Thromb Res. 76:1994;97-102.
21. Mysliwiec J., Azzadin A., Chabielska E., Takada A., Mysliwiec M., Buczko W. The effect of tacrolimus (FK506) and cyclosporin A (CyA) on peripheral serotonergic mechanisms in uremic rats. Thromb Res. 83:1996;175-181.
22. Ueda D., Suzuki K., Malyszko J., Pietraszek M.H., Takada Y., Takada A., Kawabe K. Serotonergic measures in cyclosporine A treated rats. Thromb Res. 76:1994;171-179.
23. Vanhoutte P.M. Serotonin, hypertension and vascular diseases. Neth J Med. 38:1991;35-42.
24. Azzadin A., Mysliwiec J., Wollny T., Mysliwiec M., Buczko W. Serotonin is involved in the pathogenesis of hypertension developing during erythropoietin treatment in uremic rats. Thromb Res. 77:1995;217-224.
25. Hervé P., Launay J.M., Scrobohaci M.L., Brenot F., Simonneau G., Petitpretz P., Poubeau P., Cerrina J., Duroux P., Drouet L. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 99:1995;249-254.
26. Ding Y.A., Chou T.C., Huan R. Are platelet cytosolic calcium, serotonin concentration and blood viscosity different between hypertensive and normotensive subjects? Cardiology. 85:1994;76-81.
27. Nityanand S., Tekwani B.L., Chandra M., Shanker K., Singh B.N. Kinetics of serotonin in platelets in essential hypertension. Life Sci. 46:1990;367-372.
28. Jafri S.M., Chandra M., Dhawan S., Sonid D., Chandra M., Shanker K. Factors influencing platelet serotonin uptake in essential hypertension. Int J Cardiol. 34:1992;327-333.
29. Evans S.M., Giddings J.C., Muraki T., Yamamoto J. Expression of von Willebrand factor, P-selectin (CD62P) and thrombomodulin in human endothelial cells in culture modulated by cyclosporin A. Clin Lab Haematol. 19:1997;115-122.
30. Bombeli T., Muller M., Straub P.W., Haeberli A. Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood. J Lab Clin Med. 127:1996;621-634.
31. Vanhoutte P.M. Platelets, endothelium and blood vessel wall. Experientia. 44:1988;105-108.
32. Taylor J.E., Scott N., Hill A., Bridges A., Henderson I.S., Stewart W.K., Belch J. Oxygen free radicals and platelet and granulocyte aggregability in renal transplant patients. Transplantation. 55:1993;500-504.
33. Niedelberger W., Schaub B.P., Beveridge T. High-performance liquid chromatographic determination of cyclosporin A in human plasma and urine. J Chromatogr. 182:1980;454-458.
34. Reynolds D.J.M., Aronson J.K. Cyclosporin. Br Med J. 305:1992;1491-1494.